Pharmacy Times

JUNE 27, 2025

Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. The recent application was granted both priority review and orphan drug designation. Mann School of Pharmacy and Pharmaceutical Sciences in Los Angeles.

Pharmacy Technician 22

Pharmacy Technician Diabetes Compounding Pharmacies Pharmacy Management 22

Pharmacy Times

JULY 21, 2025

Fournier, BSc Key Takeaways The 2024-2025 influenza season saw unprecedented severity, with high hospitalization and outpatient visit rates due to a vaccine mismatch and dominant H1N1 and H3N2 strains. 1 The US also reported the highest rates of hospitalizations and outpatient visits for flulike illnesses in 15 years.

Pharmacy Technician 46

Pharmacy Technician Vaccines Immunization Immunity 46

Pharmacy Times

JULY 26, 2025

1-4 About the Author Sinem Yasil is a 2026 PharmD candidate at the South College School of Pharmacy in Knoxville, Tennessee. Dabigatran is a direct thrombin inhibitor because it targets and inhibits factor IIa (thrombin) to achieve the same clinical effect. 5 A CBC provides information on an individual’s hematologic status.

Pharmacy Technician 41

Pharmacy Technician Compounding Pharmacies Diabetes Pharmacy Management 41

Pharmacy Times

JUNE 4, 2025

USP plans to continue expanding its advanced technology footprint into an additional 8,000 square foot laboratory in 2026. The Advanced Technologies Lab is the latest of USP’s investments in advanced manufacturing technologies. Learn more about USP’s supply chain solutions.

Pharmaceutical Manufacturing 26

Pharmaceutical Manufacturing Pharmacy Technician Compounding Pharmacies Compounding 26

European Pharmaceutical Review

JUNE 6, 2025

Dr Pakola shared that the trial is anticipated to support a Biologics License Application (BLA) submission for the gene therapy under accelerated approval in mid-2026. Top-line data is expected in H1 of 2026. “We are particularly encouraged by the outperformance observed in older patients”.

Hospitals 52

Hospitals 52

Pharmacy Times

JULY 4, 2025

SHOW MORE Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization. The research also demonstrated that no patients were hospitalized to treat their inflammatory condition during the study period.

Biosimilars 34

Biosimilars Specialty Pharmacies Pharmacy Technician Hospitals 34

Pharmacy Times

JULY 10, 2025

Relapse risk factors include prior hospitalizations, long illness duration, and antipsychotic polypharmacy, emphasizing the need for effective maintenance treatments. Maintaining stability in schizophrenia is a major clinical challenge—each relapse can disrupt functioning, burden caregivers, and elevate hospitalization risk.

Pharmacy Technician 20

Pharmacy Technician Hospitals Compounding Pharmacies Pharmacy Management 20

Pharmacy Times

JULY 22, 2025

Patients should be informed that the 2025-2026 influenza vaccines will be trivalent, covering 2 influenza A strains (H1N1 and an updated H3N2) and 1 B/Victoria lineage strain, as the B/Yamagata lineage is no longer circulating. 5 This option should be available for patients for the 2025-2026 flu season.

Vaccines 20

Vaccines Pharmacy Technician Immunity Immunization 20

Putting Patients First Blog

JUNE 26, 2025

While large hospitals may have dedicated reimbursement departments and billing vendors with direct access to CMS updates, smaller or rural practices often depend on Medicare Administrative Contractors (MACs) and third-party systems for claims processing guidance. 117–169, 136 Stat. 1818 (2022). Patterson, and Jonathan D. July 2, 2024.

Drug Pricing 52

Drug Pricing Communication Drug Development Documentation 52

Pharmacy Times

JULY 24, 2025

6 A new drug application (NDA) with the FDA and global regulators are expected to be filed by March 2026, according to the manufacturers. Impressively, over 95% of trial completers entered the ongoing long-term extension study, reflecting both tolerability and sustained interest among participants.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Biosimilars Pharmacy Management 26

Pharmaceutical Commerce

JUNE 9, 2025

Image Credit: Adobe Stock Images/Artur.com Key Takeaways Sanofi is shipping Beyfortus early to ensure strong supply for the 2025–2026 RSV season and avoid past shortages. Beyfortus cut RSV hospitalizations by up to 83.2% Sanofi and AstraZeneca have tripled production capacity to meet growing demand. 3 References 1. June 9, 2025.

Drug Pricing 52

Drug Pricing Vaccines Immunity Immunization 52

Pharmaceutical Technology

JULY 16, 2025

Anticipated next steps involve generating preclinical candidate data packages, which will include non-human primate studies expected in early 2026. Their efforts include exploring other oligomer-specific antibodies from Acumen’s library to identify potential lifecycle opportunities beyond sabirnetug alone.

Packaging 52

Packaging Communication Hospitals Drug Development 52

Pharmaceutical Technology

JULY 18, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmacy Times

JUNE 10, 2025

Some will assume roles in hospitals and health systems, long-term care, telehealth models, and other roles. Pharmacy schools are expected to graduate 8,000 student pharmacists in 2026…” [Instagram post]. 3,4 Now more than ever, we need additional PharmD graduates in the direct-to-career route. January 21, 2025. Accessed June 6, 2025.

Pharmacy Technician 26

Pharmacy Technician Doctor of Pharmacy Compounding Pharmacies Pharmacy Management 26

Pharmaceutical Technology

JULY 21, 2025

It is expected to enhance gross margin and contribute positively to operating income and earnings per share after 2026. July 21, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The acquisition of Blueprint provides Sanofi with a well-established foothold among allergists, dermatologists and immunologists.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 7, 2025

KalVista will receive an upfront payment of $11m, with an additional $11m contingent upon achieving a regulatory milestone anticipated by early 2026. In April 2025, KalVista Pharmaceuticals granted Kaken Pharmaceutical the commercialisation rights for sebetralstat in Japan. Sign up for our daily news round-up!

Packaging 122

Packaging Communication Hospitals Drug Pricing 122

Pharmaceutical Technology

JULY 22, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Immunity 52

Immunity Immunization Packaging Communication 52

Pharmaceutical Technology

JUNE 19, 2025

By GlobalData Learn more about Strategic Intelligence The company then plans to expand into a Phase Ib proof-of-concept trial in patients with KCNT1-related epilepsy in early 2026. The US Food and Drug Administration (FDA) has awarded ABS-1230 both orphan drug and rare paediatric designations.

Communication 52

Communication Hospitals Drug Development Pharmaceutical Manufacturing 52

Pharmaceutical Technology

JULY 25, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 24, 2025

July 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Smouldering multiple myeloma represents an asymptomatic stage in the progression to multiple myeloma. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 23, 2025

July 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The focus of the investment is a manufacturing facility dedicated to producing drug substances for AstraZeneca. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 16, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 59

Packaging Communication Hospitals Drug Pricing 59

Pharmaceutical Technology

JULY 25, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 24, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Vaccines 52

Vaccines Packaging Communication Immunity 52

Pharmaceutical Technology

JUNE 18, 2025

Experts gathered at the ongoing BIO International Convention in Boston, US, this week were reasonably confident the programme will be reauthorised in a legislative package before its expiry in September 2026. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Packaging 59

Packaging Communication Hospitals 59

Pharmaceutical Technology

JULY 1, 2025

Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 15, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Vaccines 52

Pharmaceutical Technology

JULY 23, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Communication 52

Pharmaceutical Technology

JULY 15, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Vaccines 52

Pharmaceutical Technology

JUNE 19, 2025

As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026. These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options.

Communication 52

Communication Hospitals Pharmaceutical Manufacturing Packaging 52

Pharmaceutical Technology

JULY 14, 2025

A target action date of 28 April 2026 has been set under the Prescription Drug User Fee Act (PDUFA). The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for review to treat adults with virologically suppressed human immunodeficiency virus (HIV)-1.

Packaging 52

Packaging Hospitals Communication Research Laboratories 52

Pharmaceutical Technology

JULY 21, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Diabetes 52

Diabetes Packaging Communication Hospitals 52

Putting Patients First Blog

JUNE 12, 2025

Market Basket and Payment Rate Updates Hospital Inpatient Prospective Payment System Operating and Capital Payment Rate Updates The NHC is concerned about whether CMS’ proposed 2.4 percent update to the operating payment rates for general acute care hospitals—reflecting a 3.2 percent market basket increase offset by a 0.8 percent to 0.3

Hospitals 52

Hospitals Inpatient Vaccines Communication 52

Pharmaceutical Technology

JULY 14, 2025

A decision by the FDA is expected in H1 2026. GSK’s Arexvy is already approved in the US for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk. Give your business an edge with our leading industry insights.

Labelling 52

Labelling Vaccines Insurance Coverage and Processing Packaging 52

Pharmaceutical Technology

JUNE 11, 2025

June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The company intends to introduce its inaugural product candidate into clinical trials by 2026. The company is progressing several programmes, intending to introduce its inaugural product candidate into clinical trials by 2026.

Communication 52

Communication Hospitals Packaging Vaccines 52

Pharmaceutical Technology

JULY 9, 2025

The financial impact of this agreement on JCR’s consolidated results for the fiscal year ending 31 March 2026 has already been included in the current earnings forecast. JCR values its partnership with Alexion, and we are pleased to build on the collaboration we have developed over the years.”

Insurance Coverage and Processing 52

Insurance Coverage and Processing Packaging Communication Hospitals 52

Pharmaceutical Technology

JULY 16, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Documentation 52

Documentation Communication Packaging Hospitals 52